Skip to content
LATEST
Health

Sex-Specific Immune Cell Variations Influence Obesity-Related Metabolic Risks

Researchers have identified sex-specific immune cell variations in fat tissue that influence metabolic health, suggesting that future obesity treatments may…

Sex-Specific Immune Cell Variations Influence Obesity-Related Metabolic Risks

Recent research identifies distinct variations in immune cell behavior within adipose tissue that correlate with biological sex, offering a potential explanation for disparate metabolic responses to obesity. The study highlights the role of eosinophils—immune cells traditionally associated with allergic responses—which exhibit diverse functional profiles depending on the host's sex.

High-resolution single-cell sequencing revealed six distinct populations of eosinophils in fat tissue, each possessing unique gene expression patterns. In female subjects, specific eosinophil populations appear to facilitate protective communication with macrophages, promoting metabolic stability. Conversely, male subjects demonstrated a higher prevalence of inflammatory eosinophil populations when exposed to high-fat diets, suggesting a reduced capacity for protective immune regulation.

The research identifies the protein RELM alpha as The research identifies the protein RELM alpha as a critical mediator in the communication between eosinophils and macrophages. This protein appears to stabilize beneficial immune interactions, particularly in female subjects, thereby mitigating inflammation. These findings suggest that the metabolic impact of obesity is not solely determined by the quantity of immune cells present, but by their functional characteristics and inter-cellular signaling pathways.

While these findings provide a framework for understanding sex-based differences in metabolic health, the data is currently limited to murine models. Although human adipose tissue has been shown to contain similar eosinophil populations, the specific functions of these cells in human physiology remain unverified. Future clinical development of obesity therapeutics will likely require sex-specific strategies, as immune-targeted interventions may produce divergent outcomes based on the patient's biological sex. Further research is required to determine if these pathways can be safely modulated in human clinical settings.

More stories

Latest news